Psoriasis study does little to help Pfizer with Xeljanz

Carly Helfand Rheumatoid arthritis treatment Xeljanz, while expected to grow into a big seller for Pfizer, hasn't had a fast start. The company hoped adding a psoriasis indication ...

Gilead Stopping Idelalisib Study Early Over Positive Risk-Benefit

barbara.lempert Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia Early Because of Positive Risk-Benefit FOSTER CITY, Calif.–(BUSINESS WIRE)–Oct. ...

Study: More Than Half Now Write “e-prescriptions”

barbara.lempert AJMC Study: More Than Half Now Write “e-prescriptions” Changes to federal law encouraging the use of e-prescriptions may have helped cause a jump in their use from ...

Alkermes hits key milestone on pivotal PhIII schizophrenia study

John Carroll Ireland's Alkermes has hit a key milestone in its quest to develop a long-acting version of Abilify for schizophrenia. The biotech, which has R&D operations in ...

Lubiprostone Proves to be Efficacious in Study

mia.burns Clinical Data Show That Lubiprostone is Efficacious and Well Tolerated in Children and Adolescents With Functional Constipation Results Published in Journal of Pediatric ...

Curis Starts Roche Sponsored Study for AML and MDS

mia.burns Curis Announces Initiation of a Roche-Sponsored Phase 1b/2 Study of Erivedge(R) (vismodegib) in Relapsed/Refractory AML and High Risk MDS AML and MDS Represent Non-Mutation ...

Bristol-Myers melanoma drug Yervoy helps patients live years longer, study finds

Carly Helfand When it launched in March 2011, Yervoy became the only drug ever to extend survival in patients with advanced forms of melanoma. Now, new data show just how long the breakthrough ...

Amarin Announces Enrollment of the REDUCE-IT Cardiovascular Outcomes Study Surpasses 6,000 Patients

barbara.lempert    Study Evaluating the Effectiveness of Vascepa(R) in Reducing    Major Cardiovascular Events in a High-Risk Patient Population BEDMINSTER, N.J., and DUBLIN, ...

Japan authorities digging deeper into Novartis’ use of flawed Diovan study

Eric Palmer Swiss drugmaker Novartis has repeatedly apologized after learning that a company employee was affiliated with a study in Japan of blockbuster Diovan as a statistician without ...

Study: Statin Use Raises Cataract Risk

barbara.lempert Higher Cataract Risk Appears Associated With Statin Use CHICAGO – An increased risk of cataracts, a main cause of poor vision and blindness, appears to be associated ...

$33M NIH study will explore a new drug to prevent Alzheimer’s

John Carroll The Banner Alzheimer's Institute in Phoenix has landed a $ 33 million NIH grant to see if an anti-amyloid therapy can prevent the memory-wasting condition from getting ...

NovaBay shares jump on positive PhII catheter solution study

John Carroll Shares of NovaBay Pharmaceuticals shot up 11% after the Emeryville, CA-based biotech said that a mid-stage study of a new solution to prevent problems for people with indwelling ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS